TIMOTHY CAMPBELL BURN
Pilots at Marian Ct, Hockessin, DE
License number
Delaware A4928410
Category
Airmen
Type
Authorized Aircraft Instructor
Address
Address
212 Marian Ct, Hockessin, DE 19707
Personal information
See more information about TIMOTHY CAMPBELL BURN at radaris.comName
Address
Phone
212 Marian Ct, Hockessin, DE 19707
Professional information
Nucleic Acids Encoding Aggrecan Degrading Metallo Proteases
US Patent:
6521436, Feb 18, 2003
Filed:
Aug 9, 2000
Appl. No.:
09/634286
Inventors:
Elizabeth C. Arner - West Grove PA
Timothy C. Burn - Hockessin DE
Robert A. Copeland - Hockessin DE
Carl P. Decicco - Newark DE
Ruiqin Liu - Hockessin DE
Ronald Magolda - Wallingford PA
Michael Pratta - Glassboro NJ
Kimberly A. Solomon - Landenburg PA
Micky D. Tortorella - Newark DE
James M. Trzaskos - Boothwyn PA
Fude Yang - Wilmington DE
Timothy C. Burn - Hockessin DE
Robert A. Copeland - Hockessin DE
Carl P. Decicco - Newark DE
Ruiqin Liu - Hockessin DE
Ronald Magolda - Wallingford PA
Michael Pratta - Glassboro NJ
Kimberly A. Solomon - Landenburg PA
Micky D. Tortorella - Newark DE
James M. Trzaskos - Boothwyn PA
Fude Yang - Wilmington DE
Assignee:
Bristol-Myers Squibb Company - Princeton NJ
International Classification:
C12N 964
US Classification:
435226, 435212, 435219, 435183, 4352523, 4353201, 435325, 536 231, 536 232, 536 235, 530350
Abstract:
The invention is directed to the family of aggrecan degrading metallo proteases (ADMPs) that exhibit the ability to cleave the aggrecan core protein between amino acid residues Glu -Ala. The invention encompasses the nucleic acids encoding such enzymes, processes for production of recombinant ADMPs, compositions containing such enzymes, and the use of these enzymes in various assays and for the development of novel inhibitors for use as therapies for diseases involving aggrecanase-mediated degradation of cartilage or other aggrecanase-associated diseases.
Kvlqt1ÂA Long Qt Syndrome Gene
US Patent:
6420124, Jul 16, 2002
Filed:
Jun 19, 2000
Appl. No.:
09/597735
Inventors:
Mark T. Keating - Brookline MA
Michael C. Sanguinetti - Salt Lake City UT
Mark E. Curran - Newark CA
Gregory M. Landes - Northboro MA
Timothy D. Connors - Hopkinton MA
Timothy C. Burn - Hockessin DE
Igor Splawski - Allston MA
Michael C. Sanguinetti - Salt Lake City UT
Mark E. Curran - Newark CA
Gregory M. Landes - Northboro MA
Timothy D. Connors - Hopkinton MA
Timothy C. Burn - Hockessin DE
Igor Splawski - Allston MA
Assignee:
University of Utah Research Foundation - Salt Lake City UT
Genzyme Corporation - Framingham MA
Genzyme Corporation - Framingham MA
International Classification:
G01N 3353
US Classification:
435 71, 435 72, 435 721, 436507
Abstract:
The genomic structure including the sequence of the intron/exon junctions is disclosed for KVLQT1 and KCNE1 which are genes associated with long QT syndrome. Additional sequence data for the two genes ARE also disclosed. Also disclosed are newly found mutations in KVLQT1 which result in long QT syndrome. The intron/exon junction sequence data allow for the design of primer pairs to amplify and sequence across all of the exons of the two genes. This can be used to screen persons for the presence of mutations which cause long QT syndrome. Assays can be performed to screen persons for the presence of mutations in either the DNA or proteins. The DNA and proteins may also be used in assays to screen for drugs which will be useful in treating or preventing the occurrence of long QT syndrome.
Kvlqt1ÂA Long Qt Syndrome Gene
US Patent:
6451534, Sep 17, 2002
Filed:
Jun 19, 2000
Appl. No.:
09/597732
Inventors:
Mark T. Keating - Salt Lake City UT
Michael C. Sanguinetti - Salt Lake City UT
Mark E. Curran - Encinitas CA
Gregory M. Landes - Northboro MA
Timothy D. Connors - Hopkinton MA
Timothy C. Burn - Hockessin DE
Igor Splawski - Salt Lake City UT
Michael C. Sanguinetti - Salt Lake City UT
Mark E. Curran - Encinitas CA
Gregory M. Landes - Northboro MA
Timothy D. Connors - Hopkinton MA
Timothy C. Burn - Hockessin DE
Igor Splawski - Salt Lake City UT
Assignee:
University of Utah Research Foundation - Salt Lake City UT
Genzyme Corporation - Framingham MA
Genzyme Corporation - Framingham MA
International Classification:
C12Q 168
US Classification:
435 6, 536 2433, 536 235
Abstract:
The genomic structure including the sequence of the intron/exon junctions is disclosed for KVLQT1 and KCNE1 which are genes associated with long QT syndrome. Additional sequence data for the two genes ARE also disclosed. Also disclosed are newly found mutations in KVLQT1 which result in long QT syndrome. The intron/exon junction sequence data allow for the design of primer pairs to amplify and sequence across all of the exons of the two genes. This can be used to screen persons for the presence of mutations which cause long QT syndrome. Assays can be performed to screen persons for the presence of mutations in either the DNA or proteins. The DNA and proteins may also be used in assays to screen for drugs which will be useful in treating or preventing the occurrence of long QT syndrome.
Aggrecan Degrading Metallo Proteases
US Patent:
6451575, Sep 17, 2002
Filed:
Jul 24, 1998
Appl. No.:
09/122126
Inventors:
Elizabeth C. Arner - West Grove PA
Timothy C. Burn - Hockessin DE
Robert A. Copeland - Hockessin DE
Carl P. Decicco - Newark DE
Ruiqin Liu - Hockessin DE
Ronald Magolda - Wallingford PA
Michael Pratta - Glassboro NJ
Kimberly A. Solomon - Landenburg PA
Micky D. Tortorella - Newark DE
James M. Trzaskos - Boothwyn PA
Fude Yang - Wilmington DE
Timothy C. Burn - Hockessin DE
Robert A. Copeland - Hockessin DE
Carl P. Decicco - Newark DE
Ruiqin Liu - Hockessin DE
Ronald Magolda - Wallingford PA
Michael Pratta - Glassboro NJ
Kimberly A. Solomon - Landenburg PA
Micky D. Tortorella - Newark DE
James M. Trzaskos - Boothwyn PA
Fude Yang - Wilmington DE
Assignee:
Bristol-Myers Squibb Pharma Company - Princeton NJ
International Classification:
C12N 964
US Classification:
435226, 435212, 435219, 435183, 435 23, 530350, 424 9467
Abstract:
The invention is directed to the family of aggrecan degrading metallo proteases (ADMPs) that exhibit the ability to cleave the aggrecan core protein between amino acid residues Glu -Ala. The invention encompasses the nucleic acids encoding such enzymes, processes for production of recombinant ADMPs, compositions containing such enzymes, and the use of these enzymes in various assays and for the development of novel inhibitors for use as therapies for diseases involving aggrecanase-mediated degradation of cartilage or other aggrecanase-associated diseases.
Diagnostic Method For Kvlqt1ÂA Long Qt Syndrome Gene
US Patent:
6582913, Jun 24, 2003
Filed:
Jun 19, 2000
Appl. No.:
09/597731
Inventors:
Mark T. Keating - Salt Lake City UT
Michael C. Sanguinetti - Salt Lake City UT
Mark E. Curran - Encinitas CA
Gregory M. Landes - Northboro MA
Timothy D. Connors - Hopkinton MA
Timothy C. Burn - Hockessin DE
Igor Splawski - Salt Lake City UT
Michael C. Sanguinetti - Salt Lake City UT
Mark E. Curran - Encinitas CA
Gregory M. Landes - Northboro MA
Timothy D. Connors - Hopkinton MA
Timothy C. Burn - Hockessin DE
Igor Splawski - Salt Lake City UT
Assignee:
University of Utah Research Foundation - Salt Lake City UT
Genzyme, Inc. - Framingham MA
Genzyme, Inc. - Framingham MA
International Classification:
C12Q 168
US Classification:
435 6
Abstract:
The genomic structure including the sequence of the intron/exon junctions is disclosed for KVLQT1 and KCNE1 which are genes associated with long QT syndrome. Additional sequence data for the two genes ARE also disclosed. Also disclosed are newly found mutations in KVLQT1 which result in long QT syndrome. The intron/exon junction sequence data allow for the design of primer pairs to amplify and sequence across all of the exons of the two genes. This can be used to screen persons for the presence of mutations which cause long QT syndrome. Assays can be performed to screen persons for the presence of mutations in either the DNA or proteins. The DNA and proteins may also be used in assays to screen for drugs which will be useful in treating or preventing the occurrence of long QT syndrome.
Assay For Ppar Ligand Dependent Gene Modulation
US Patent:
2004010, Jun 3, 2004
Filed:
Sep 16, 2003
Appl. No.:
10/663002
Inventors:
Ranjan Mukherjee - Churchville PA, US
Phillip Liu - Wilmington DE, US
Reid Huber - Wilmington DE, US
Timothy Burn - Hockessin DE, US
Peter Young - San Francisco CA, US
Phillip Liu - Wilmington DE, US
Reid Huber - Wilmington DE, US
Timothy Burn - Hockessin DE, US
Peter Young - San Francisco CA, US
International Classification:
C12Q001/68
US Classification:
435/006000
Abstract:
The peroxisome proliferator activated receptor alpha (PPAR) plays a key role in mediating fatty acid metabolism by regulating expression of genes involved in fatty acid oxidation. A limitation of existing human cell models for testing PPAR ligands is the inability to detect PPAR responsive genes with endogenous levels of PPAR protein. The HK-2 cell line derived from human proximal tubules showed induction of several genes, including pyruvate dehydrogenase kinase 4 (PDK-4) and adipocyte differentiation related factor (ADRP) by PPAR ligands. Induction of PDK-4 by PPAR agonists in the HK-2 cell model closely correlates with its induction in vivo and thus represents a marker for PPAR agonist action. HK2 cells also exemplify the first model of a human cell line in which PPAR ligand dependent gene induction can be detected with endogenous levels of receptor.
Compositions, Methods And Kits Relating To Her-2 Cleavage
US Patent:
2012026, Oct 18, 2012
Filed:
Dec 23, 2011
Appl. No.:
13/336587
Inventors:
Steven M. Friedman - West Chester PA, US
Peggy A. Scherle - Media PA, US
Xiangdong Liu - Metchuen NJ, US
Timothy C. Burn - Hockessin DE, US
Reid Huber - Wilmington DE, US
Phillip C.C. Liu - Wilmington DE, US
Gregory F. Hollis - Wilmington DE, US
Krishna Vaddi - Hockessin DE, US
Jordan S. Fridman - Newark DE, US
Peggy A. Scherle - Media PA, US
Xiangdong Liu - Metchuen NJ, US
Timothy C. Burn - Hockessin DE, US
Reid Huber - Wilmington DE, US
Phillip C.C. Liu - Wilmington DE, US
Gregory F. Hollis - Wilmington DE, US
Krishna Vaddi - Hockessin DE, US
Jordan S. Fridman - Newark DE, US
International Classification:
A61K 31/496, A61K 38/20, A61K 38/21, A61K 31/495, A61P 35/00, A61K 31/541, A61K 31/444, A61K 31/713, A61P 35/04, A61K 39/395, A61K 31/472
US Classification:
424 852, 4241381, 4241301, 424 854, 4241331, 51425313, 51425501, 514309, 5142278, 514278, 514 44 A
Abstract:
The present invention relates to compositions, methods and kits based on the ADAM-mediated cleavage of Her-2. The present invention also relates to treatments for cancer, and in particular, breast cancer, by modulating the ADAM-mediated cleavage of Her-2. Further, the invention relates to compositions, methods and kits based on the surprising synergistic effect between inhibition of Her-2 cleavage by an ADAM and certain cytostatic (e.g., Herceptin) and cytotoxic (e.g., Taxol) compounds in, among other things, inhibiting tumor cell proliferation and inducing cell death. Additionally, the invention relates to novel variants of ADAM15, designated ADAM15 variant 1 and ADAM15 variant 2, now identified and isolated.
Compositions, Methods And Kits Relating To Her-2 Cleavage
US Patent:
8088737, Jan 3, 2012
Filed:
Apr 2, 2004
Appl. No.:
10/817718
Inventors:
Steven M. Friedman - West Chester PA, US
Peggy A. Scherle - Media PA, US
Xiangdong Liu - Metchuen NJ, US
Timothy C. Burn - Hockessin DE, US
Reid Huber - Wilmington DE, US
Phillip C. C. Liu - Wilmington DE, US
Gregory F. Hollis - Wilmington DE, US
Krishna Vaddi - Hockessin DE, US
Jordan S. Fridman - Newark DE, US
Peggy A. Scherle - Media PA, US
Xiangdong Liu - Metchuen NJ, US
Timothy C. Burn - Hockessin DE, US
Reid Huber - Wilmington DE, US
Phillip C. C. Liu - Wilmington DE, US
Gregory F. Hollis - Wilmington DE, US
Krishna Vaddi - Hockessin DE, US
Jordan S. Fridman - Newark DE, US
Assignee:
Incyte Corporation - Wilmington DE
International Classification:
A01N 61/00, A61K 31/00, A61K 38/00, A61K 39/395, G01N 33/48
US Classification:
514 193, 4241301, 4241381, 436 64, 514 1, 514 11, 514 192, 514 194, 514 198, 514 201
Abstract:
The present invention relates to compositions, methods and kits based on the ADAM-mediated cleavage of Her-2. The present invention also relates to treatments for cancer, and in particular, breast cancer, by modulating the ADAM-mediated cleavage of Her-2. Further, the invention relates to compositions, methods and kits based on the surprising synergistic effect between inhibition of Her-2 cleavage by an ADAM and certain cytostatic (e. g. , Herceptin) and cytotoxic (e. g. , Taxol) compounds in, among other things, inhibiting tumor cell proliferation and inducing cell death. Additionally, the invention relates to novel variants of ADAM15, designated ADAM15 variant 1 and ADAM15 variant 2, now identified and isolated.
Kvlqt1--A Long Qt Syndrome Gene
US Patent:
6277978, Aug 21, 2001
Filed:
Aug 17, 1998
Appl. No.:
9/135010
Inventors:
Mark T. Keating - Brookline MA
Michael C. Sanguinetti - Salt Lake City UT
Mark E. Curran - Newark CA
Gregory M. Landes - Livermore CA
Timothy D. Connors - Hopkinton MA
Timothy C. Burn - Hockessin DE
Igor Splawski - Allston MA
Michael C. Sanguinetti - Salt Lake City UT
Mark E. Curran - Newark CA
Gregory M. Landes - Livermore CA
Timothy D. Connors - Hopkinton MA
Timothy C. Burn - Hockessin DE
Igor Splawski - Allston MA
Assignee:
University of Utah Research Foundation - Salt Lake City UT
Genzyme Corporation - Framingham MA
Genzyme Corporation - Framingham MA
International Classification:
C07K 14705, C12N 1512, C12N 516
US Classification:
536 235
Abstract:
The genomic structure including the sequence of the intron/exon junctions is disclosed for KVLQT1 and KCNE1 which are genes associated with long QT syndrome. Additional sequence data for the two genes are also disclosed. Also disclosed are newly found mutations in KVLQT1 which result in long QT syndrome. The intron/exon junction sequence data allow for the design of primer pairs to amplify and sequence across all of the exons of the two genes. This can be used to screen persons for the presence of mutations which cause long QT syndrome. Assays can be performed to screen persons for the presence of mutations in either the DNA or proteins. The DNA and proteins may also be used in assays to screen for drugs which will be useful in treating or preventing the occurrence of long QT syndrome.
Antibodies To Aggrecan-Degrading Metalloprotease And Diagnostic Methods Using Same
US Patent:
7049412, May 23, 2006
Filed:
Aug 9, 2000
Appl. No.:
09/634287
Inventors:
Elizabeth C. Arner - West Grove PA, US
Timothy C. Burn - Hockessin DE, US
Robert A. Copeland - Hockessin DE, US
Carl P. Decicco - Newark DE, US
Ruiqin Liu - Hockessin DE, US
Ronald Magolda - Wallingford PA, US
Michael Pratta - Glassboro NJ, US
Kimberly A. Solomon - Landenburg PA, US
Micky D. Tortorella - Newark DE, US
James M. Trzaskos - Boothwyn PA, US
Fude Yang - Wilmington DE, US
Timothy C. Burn - Hockessin DE, US
Robert A. Copeland - Hockessin DE, US
Carl P. Decicco - Newark DE, US
Ruiqin Liu - Hockessin DE, US
Ronald Magolda - Wallingford PA, US
Michael Pratta - Glassboro NJ, US
Kimberly A. Solomon - Landenburg PA, US
Micky D. Tortorella - Newark DE, US
James M. Trzaskos - Boothwyn PA, US
Fude Yang - Wilmington DE, US
Assignee:
Bristol-Myers Squibb Pharma Comp. - Princeton NJ
International Classification:
C07K 16/00
US Classification:
53038826, 5303891, 435 71, 435 74
Abstract:
The invention is directed to the family of aggrecan degrading metallo proteases (ADMPs) that exhibit the ability to cleave the aggrecan core protein between amino acid residues Glu-Ala. The invention encompasses the nucleic acids encoding such enzymes, processes for production of recombinant ADMPs, compositions containing such enzymes, and the use of these enzymes in various assays and for the development of novel inhibitors for use as therapies for diseases involving aggrecanase-mediated degradation of cartilage or other aggrecanase-associated diseases.